Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
Bruker showcased its expanding Microbiology & Infection Diagnostics portfolio at ASM Microbe 2026, highlighting new FDA-cleared capabilities for the MALDI Biotyper CA System and new RUO/GP solutions for the U.S. market. The company reported robust demand in its U.S. microbiology business, citing 140 new system placements in 2025 and double-digit consumables growth that has continued into 2026.
Key figures
- Consumables growth
- double-digit
- Ruo library species
- 5325
- New ru O species added
- 600
- Microbial species library
- 549
- New system placements 2025
- 140
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.